New Search

If you are not happy with the results below please do another search

15 search results for: nasal spray

11

Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections

ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations Survey was conducted through COPD360Net®, an innovative COPD Foundation program that identifies unmet patient needs and integrates the patient voice into therapy development Miami, Fla., and Melbourne, Australia, 30th January 2023 – A […]

12

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D., to Board of Directors Sydney, Australia, 15 June – ENA Respiratory, a biotechnology company developing a first-in-class […]

13

ENA Respiratory announces an extension of its Series A and positive COVID-19 ferret challenge study results

A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu, has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveal. The novel product, INNA-051, being developed by Australian biotech company, Ena Respiratory, reduced viral replication by up to 96 percent in a gold-standard […]

15

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats Melbourne, Australia – Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense (DoD) to support ongoing research and development of INNA-051, a clinical stage first-in-class broad-spectrum antiviral innate immunomodulator, administered […]